Intravenous immunoglobulin in macrophage activation syndrome associated with systemic lupus erythematosus
Main Article Content
Keywords
Lupus Erythematosus, Systemic, Macrophage Activation Syndrome, Hemophagocytic, Lymphohistiocytosis
Abstract
Background: The hemophagocytic lymphohistiocytosis is a disease with a potential fatal evolution, caused by the activation of macrophages and histiocytes with hemophagocytosis in bone marrow and other reticuloendothelial systems, triggered by a defect in the T lymphocyte when stimulating the production of interleukin 1-beta, interleukin 6, interferon-gamma and tumor necrosis factor-alpha that promote macrophage activation. This condition presents with fever, cytopenias, splenomegaly, hemophagocytosis in bone marrow, hypertriglyceridemia and hypofibrinogenemia, in the context of an infectious, neoplastic or autoimmune disease. The objective of this article is to describe the utility of intravenous immunoglobulin (IVIg) in patients unable to receive immunosuppressive treatment.
Case reports: We present two case reports of systemic lupus erythematosus (SLE) with macrophage activation syndrome (MAS), one of them associated with central nervous system vasculitis and the other one with febrile neutropenia, both with bacterial infection added.
Conclusions: The diagnosis of MAS should be suspected in all patients with lupus activity, fever, cytopenias, visceromegalies, hypertriglyceridemia and hypofibrinogenemia. Diagnosis and treatment are important to significantly reduce mortality. It is proposed that the first line treatment in patients that present SLE associated with MAS and sepsis should be IgIV and as a second line immunosuppressants with intravenous steroids.
References
1. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis:possible relationship to drug or infection. J Pediatr. 1985;106:561-6.
2. Carvalheiras G, Anjo D, Mendonça T, Vasconcelos C, Farinha F. Hemophagocytic syndrome as one of the main primary manifestations in acute systemic lupus erythematosus —case report and literature review. Lupus. 2010;19(6):756-61.
3. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmunity Reviews. 2004;3(2):69-75.
4. Schulert G, Grom A. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Ann Rev Med. 2015;66(1):145-59.
5. García M, Calvo JE, Duarte J, Romero S. Síndrome hemofagocítico. Reporte de un caso y revisión de bibliografía. Med Int Mex. 2013;29(1):101-5.
6. Aoyama-Maeda N, Horino T, Ichii O, Terada Y. Macrophage activation syndrome associated with systemic lupus erythematosus treated successfully with the combination of steroid pulse, immunoglobulin and tacrolimus. Rom J Intern Med. 2018;56(2):117-21. doi:10.1515/rjim-2017-0043
7. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis:report of five cases. J Pediatr. 1996;129(5):750-4. doi:10.1016/s0022-3476(96)70160-9
8. Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 2001;68(1):4-10. doi:10.1002/ajh.1141
9. Takahashi N, Naniwa T, Banno, S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol. 2008;18:72-5.
10. Sterba G, Sterba Y, Iglesias A. Macrophage activation syndrome in adults with rheumatic disease. Revista Colombiana de Reumatología (English Edition). 2016;23(2):137-43. doi:10.1016/j.rcreue.2016.05.001
11. Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015;11(9):1043-53. doi:10.1586/1744666X.2015.1058159
12. Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol. 2014;66(8):2297-307. doi:10.1002/art.38672
13. Kumakura S, Ishikura H, Endo J, Kobayashi S. Autoimmune-associated hemophagocytosis. Am J Hematol. 1995;50:148-9.
14. Kumakura S, Ishikura H, Umagae N, Yamagata S, Kobayashi S. Autoimmune-associated hemophagocytosis syndrome. Am J Med. 1997;102:113-5.
15. Kumakura S, Kondo M, Murakawa Y, Ishikura H, Masuda J, Kobayashi S. Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol. 2004;14:205-15.
16. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31, doi:10.1002/pbc.21039
17. Rosário C, Zandman-Goddard G, Meyron-Holtz E, D'Cruz D, Shoenfeld Y. The hyperferritinemic syndrome:macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
18. Hahn B, McMahon M, Wilkinson A, Wallace W, Daikh D, Fitzgerald J, et al. American College of Rheumatology Guidelines for screening, case definition, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808. doi:10.1002/acr.21664
19. Gladman D, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-91.
20. Mootsikapun P, Sirijerachai C, Chansung K, Nanagara R. Acute lupus hemophagocytic syndrome:report of a case and review of the literature. J Med Assoc Thai. 2004;87(3):333-9.
21. Botelho C, Ferrer F, Francisco L, Maia P, Mendes T, Carreira A. Acute lupus hemophagocytic syndrome:report of a case. Nefrologia. 2010;30(2):247-51.
22. Egües CA, Uriarte M, Meneses C, Aldasoro C, Rubio IH, Belzunegui J. Hemophagocytic syndrome as the initial manifestation of systemic lupus erythematosus. Reumatol Clin. (English Edition). 2014;10(5):321-4.
23. Granata G, Didona D, Stifano G, Granata M. Macrophage activation syndrome as onset of systemic lupus erythematosus:a case report and a review of the literature. Case Reports Med. 2015;2015:1-4.
24. Balduini CL, Noris P, Loni C, Aiosa C. Hemophagocytic syndrome responding to high dose gammaglobulin as presenting feature of sarcoidosis. Am J Hematol. 1997;54:88-9.
25. Mostaza JL, Guerra J, Carriedo D, Ruiz de Morales JMG. Linfohistiocitosis hemofagocítica asociada a infecciones virales:reto diagnóstico y dilema terapéutico. Rev Clin Esp. 2014;214(6):320-7.
26. Torres A, Solís E, Zeferino M, Céspedes A, Sánchez B. Síndrome de activación de macrófago como manifestación inicial de lupus eritematoso sistémico severo de inicio juvenil. Respuesta favorable a ciclofosfamida. Reumatol Clin. 2014;10(5):331-5.
27. Liu A, Yang Y, Li M, Jia Y, Chen S, Ye S, et al. Macrophage activation syndrome in systemic lupus erythematosus:a multicenter, case-control study in China. Clin Rheumatol. 2017;37(1):93-100.
28. Tothova Z, Berliner N. Hemophagocytic syndrome and critical illness:new insights into diagnosis and management. J Intensive Care Med. 2015;30(7):401-12. doi:10.1177/0885066613517076
29. Nomura S, Koshikawa K, Hamamoto K, Okubo S, Yasunaga K. Steroid and gamma globulin therapy against virus associated hemophagocytic syndrome. Rinsho Ketsueki. 1992;33:1242-7.
30. Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease:report of twenty-six cases and literature review. Arthritis Rheum. 2003;49(5):633-9. doi:10.1002/art.11368
31. Gill DS, Spencer A, Cobcroft RG. High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome. Br J Haematol. 1994;88(1):204-6. doi:10.1111/j.1365-2141.1994.tb05000.x
32. Dumancas CY, Garay Reyes HA, Cosico J, Savadkar A, Lah S. Streptococcus pneumoniae-related hemophagocytic lymphohistiocytosis treated with intravenous immunoglobulin (IVIG) and steroids. Am J Case Rep. 2018;19:258. doi:10.12659/AJCR.906590
33. La Rosée P. Treatment of hemophagocytic lympho histiocytosis in adults. Hematology. 2015;2015(1):1906.
34. Nossent JC, Swaak AJG. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Quart J Med. 1991;80:60512.
35. Michael SR, Vural IL, Bassen FA, Schaefer L. The hematological aspects of disseminated (systemic) lupus erythematosus. Blood. 1951;6:1059-72.
36. Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH. Systemic lupus erythematosus:review of the literature and clinical analysis of 138 cases. Medicine (Baltimore). 1954;33(4):291-437.
37. Raschke R, Garcia-Orr R. Hemophagocytic lymphohistiocytosis:a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest. 2011;140(4):933-8.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.